abrdn plc Grows Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

abrdn plc increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 552.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 219,900 shares of the biopharmaceutical company’s stock after buying an additional 186,215 shares during the quarter. abrdn plc’s holdings in Regeneron Pharmaceuticals were worth $193,136,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Greenleaf Trust raised its position in Regeneron Pharmaceuticals by 3.4% in the fourth quarter. Greenleaf Trust now owns 1,903 shares of the biopharmaceutical company’s stock valued at $1,671,000 after purchasing an additional 63 shares during the period. Fidelis Capital Partners LLC purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $320,000. Xponance Inc. raised its position in Regeneron Pharmaceuticals by 6.3% in the fourth quarter. Xponance Inc. now owns 14,376 shares of the biopharmaceutical company’s stock valued at $12,626,000 after purchasing an additional 852 shares during the period. AIA Group Ltd raised its position in Regeneron Pharmaceuticals by 13.6% in the fourth quarter. AIA Group Ltd now owns 4,722 shares of the biopharmaceutical company’s stock valued at $4,147,000 after purchasing an additional 565 shares during the period. Finally, Delta Financial Advisors LLC raised its position in Regeneron Pharmaceuticals by 7.8% in the fourth quarter. Delta Financial Advisors LLC now owns 1,380 shares of the biopharmaceutical company’s stock valued at $1,212,000 after purchasing an additional 100 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Sanford C. Bernstein began coverage on Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price on the stock. Morgan Stanley boosted their price target on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 13th. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Cantor Fitzgerald restated a “neutral” rating and issued a $925.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday, April 15th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 9th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $976.41.

Insider Activity

In other news, Director Joseph L. Goldstein sold 2,707 shares of the company’s stock in a transaction dated Tuesday, January 23rd. The shares were sold at an average price of $950.00, for a total value of $2,571,650.00. Following the completion of the sale, the director now directly owns 6,382 shares of the company’s stock, valued at $6,062,900. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, Director Joseph L. Goldstein sold 2,707 shares of the company’s stock in a transaction dated Tuesday, January 23rd. The shares were sold at an average price of $950.00, for a total value of $2,571,650.00. Following the completion of the sale, the director now directly owns 6,382 shares of the company’s stock, valued at $6,062,900. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The disclosure for this sale can be found here. Over the last three months, insiders sold 13,729 shares of company stock valued at $13,124,641. Insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded up $2.83 during trading hours on Friday, hitting $896.82. The company had a trading volume of 507,466 shares, compared to its average volume of 412,356. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. Regeneron Pharmaceuticals, Inc. has a 1-year low of $684.80 and a 1-year high of $998.33. The company has a market cap of $98.43 billion, a PE ratio of 25.81, a price-to-earnings-growth ratio of 2.58 and a beta of 0.11. The business has a 50 day moving average of $953.01 and a 200-day moving average of $891.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. During the same quarter in the prior year, the firm posted $10.96 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up .6% on a year-over-year basis. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.59 EPS for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.